EMEA-001832-PIP01-15-M02

Key facts

Invented name
Maviret
Active substance
  • glecaprevir
  • pibrentasvir
Therapeutic area
Infectious diseases
Decision number
P/0128/2019
PIP number
EMEA-001832-PIP01-15-M02
Pharmaceutical form(s)
  • Tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of chronic hepatitis C
Route(s) of administration
Oral use
Contact for public enquiries
AbbVie Ltd

E-mail: paediatricteam@abbvie.com
Tel. +44 (0)1628 925033

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating